Dáil Éireann Debate, Tuesday - 14 November 2023
561. Deputy Thomas Pringle asked the Minister for Health what is causing the shortage of the diabetes medication ozempic (semaglutide); the reason the HSE is overruling GP recommendations that it be prescribed to their patients; and if he will make a statement on the matter. [49795/23]
View answerOzempic (Semaglutide) is a medication indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Novo Nordisk markets Ozempic in Ireland.
To date, there have been particular challenges in the supply of Ozempic to all markets, including to the Irish market.
Novo Nordisk, has advised of supply issues with its GLP-1 receptor agonist products including Ozempic and Saxenda. The pre-existing supply issues are due to increased global demand for these products and subsequent manufacturing capacity constraints and will continue throughout 2023 and into 2024. These supply issues are not unique to Ireland and increases in demand for these medications and supply constraints have been observed in the UK, throughout the EU and across the world in recent months. Shortages of Ozempic are linked to the increased demand which has been attributed to the off-label use of the product to treat obesity.
Novo Nordisk has implemented monthly allocation to pharmacies to help ensure continuity of supply and equitable distribution of Ozempic stock to Irish patients. The company has issued advisory letters to healthcare professionals to ensure they are aware of these supply issues and how to manage them.
Novo Nordisk is continuing to work on increasing its capacity to produce more of this medication. The HPRA is engaging closely with the company and the wholesalers involved in the supply of this product. This is to closely monitor available stock and to keep the health system and the public informed.
There are a number of authorised alternative medicines indicated for treating adults with insufficiently controlled type 2 diabetes mellitus are available at this time, including other glucagon-like peptide (GLP-1) receptor agonists. Where this shortage impacts ongoing treatment for a patient, prescribers and pharmacists, in conjunction with patients, should discuss with their Healthcare professional the most appropriate course of action, based on suitable alternative treatment options available.
The Department of Health, along with relevant experts from the HSE, HPRA, Pharmaceutical Society of Ireland and the Medical Council are continuing to work together during this time of limited supply to mitigate the impact of the shortages on patients.
